A Phase 1, Single Center, Randomized, Controlled Platform Study Validating the Use of Candin as a Challenge Agent in Healthy Volunteers or Patients Given Concomitant Approved Interventions
Latest Information Update: 01 Nov 2021
At a glance
- Drugs Candida antigen (Primary) ; Tofacitinib (Primary)
- Indications Hypersensitivity
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
Most Recent Events
- 26 Oct 2021 Status changed from recruiting to completed.
- 18 Aug 2021 Status changed from not yet recruiting to recruiting.
- 10 Aug 2021 New trial record